20.01.2021Tom Shepherd as Chief Executive Officer
Captor Therapeutics S.A. announces the appointment of Tom Shepherd, Ph.D., as Chief Executive Officer
22.12.2020Captor Therapeutics and Sosei Heptares Enter Strategic Collaboration
Focused on Targeted GPCR Degradation as Novel Approach for Drug Design
22.10.2020Captor Therapeutics as one of the „Scrip’s 10 To Watch”
We have been selected as one of the „Scrip’s 10 To Watch” companies at #BIOEurope Digital 2020!
24.04.2020A new project in the area of autoimmune diseases
We have received over 27 M PLN grant for a new project!
05.03.2020Advancing the technological platform
A new grant will support...
21.02.2020Captor's review article
Our review on protein degradation technology has been published in "Technology Transfer and Entrepreneurship"...
30.01.2020Captor's oncological program received funding
Discovery and development of a new clinical drug candidate in the treatment of hepatocellular carcinoma...
19.12.2019Our new chemistry lab
We are happy to announce that our brand new chemistry lab is ready!
02.12.2019Dr Tom Shepherd joins our team
Tom Shepherd, Ph.D. as Captor Therapeutics' Chief Business Officer (CBO)...
30.07.2019Biotech of the Week in Labiotech
Labiotech about Captor Therapeutics...